

## Court Report

By [Sherri Oslick](#) -- February 12, 2012



*About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.*

### ***Purdue Pharma L.P. et al. v. Sandoz Inc.***

1:12-cv-00897; filed February 3, 2012 in the Southern District of New York

- Plaintiffs: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes Technologies, Board of Regents of the University of Texas Systems, Grunenthal GMBH

- Defendant: Sandoz Inc.

Infringement of U.S. Patent Nos. [6,488,963](#) ("Hot-Melt Extrudable Pharmaceutical Formulation," issued December 3, 2002), [7,674,799](#) ("Oxycodone Hydrochloride Having Less Than 25 PPM 14-Hydroxycodone," issued March 9, 2010), [7,674,800](#) (same title, issued March 9, 2010), [7,683,072](#) (same title, issued March 23, 2010), and [7,776,314](#) ("Abuse-Proofed Dosage System," issued August 17, 2010) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint [here](#).

### ***Shire LLC et al. v. Mylan Pharmaceuticals, Inc. et al.***

2:12-cv-00638; filed February 2, 2012 in the District Court of New Jersey

- Plaintiffs: Shire LLC; Shire Development Inc.
- Defendants: Mylan Pharmaceuticals, Inc.; Mylan Inc.; Johnson Matthey Pharmaceutical Materials; Johnson Matthey Inc.

Infringement of U.S. Patent Nos. Nos. [7,105,486](#) ("Abuse-resistant Amphetamine Compounds," issued September 12, 2006), [7,223,735](#) ("Abuse Resistant Lysine Amphetamine Compounds," issued May 29, 2007), [7,655,630](#) ("Abuse-Resistant Amphetamine Prodrugs," issued February 2, 2010), [7,659,253](#) (same title, issued February 9, 2010), [7,659,254](#) (same title, issued February 9, 2010), [7,662,787](#) ("Abuse Resistant Lysine Amphetamine Compounds," issued February 16, 2010), [7,671,030](#) ("Abuse-Resistant Amphetamine Prodrugs," issued on March 2, 2010), [7,671,031](#) (same title, issued on March 2, 2010), [7,674,774](#) (same title, issued on March 9, 2010), [7,678,770](#) (same title, issued on March 16, 2010), [7,678,771](#) (same title, issued on March 16, 2010), [7,687,466](#) (same title, issued on March 30, 2010), [7,687,467](#) (same title, issued on March 30, 2010), [7,718,619](#) (same title, issued on May 18, 2010), and [7,723,305](#) (same title, issued on May 25, 2010) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Shire's Vyvanse® (lisdexamfetamine dimesylate, used to treat Attention Deficit Hyperactivity Disorder). View the complaint [here](#).

"Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.